Cancer Therapy and Osteoporosis: Approach to Evaluation and Management

Seminars in Oncology

Volumn 35, Issue 6, 2008, Pages 643-651

  van Londen, G J ^a   Taxel, Pamela ^b   Van Poznak, Catherine ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

AGING; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; VITAMIN SUPPLEMENTATION;

AGING; HUMANS; NEOPLASMS; OSTEOPOROSIS;

EID: 56249130099     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.08.008     Document Type: Article

References (75)

1. Physician's guide to prevention and treatment of osteoporosis (2003), National Osteoporosis Foundation, Washington, DC. www.nof.org accessed July 5, 2008
2. Binkley N., Bilezikian J.P., Kendler D.L., Leib E.S., Lewiecki E.M., and Petak S.M. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 9 (2006) 4-14
3. Melton III L.J., and Riggs B.L. Epidemiology of age-related fractures. In: Avioli L.V. (Ed). The osteoporotic syndrome (1983), Grune & Stratton, New York 45-72
4. Hadjidakis D.J., and Androulakis II. Bone remodeling. Ann N Y Acad Sci 1092 (2006) 385-396
5. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115 (2005) 3318-3325
6. Taxel P., Fall P.M., Albertsen P.C., Dowsett R.D., Trahiotis M., Zimmerman J., et al. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 4907-4913
7. Meier C., Nguyen T.V., Handelsman D.J., Schindler C., Kushnir M.M., Rockwood A.L., et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168 (2008) 47-54
8. Mellström D., Vandenput L., Mallmin H., Holmberg A.H., Lorentzon M., Oden A., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. Epub ahead of print June 2 (2008) 18518773
9. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17 (2006) 1726-1733
10. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
11. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353 (2005) 595-603
12. Ebeling P.R. Clinical practice. Osteoporosis in men. N Engl J Med 358 (2008) 1474-1482
13. National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htm accessed July 5, 2008
14. Wachtel T.J. Geriatric osteoporosis. Med Health R I 90 (2007) 330-333
15. Andersen S.J. Osteoporosis in the older woman. Clin Obstet Gynecol 50 (2007) 752-766
16. Preventing falls among older adults. CDC. http://www.cdc.gov/ncipc/factsheets/adultfalls.htm accessed July 5, 2008
17. Kannus P., Parkkari J., Niemi S., Pasanen M., Palvanen M., Jarvinen M., et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 343 (2000) 1506-1513
18. Parker M.J., Gillespie W.J., and Gillespie L.D. Effectiveness of hip protectors for preventing hip fractures in elderly people: a systematic review. BMJ 332 (2006) 571-574
19. Raisz L.G. Clinical practice. Screening for osteoporosis. N Engl J Med 353 (2005) 164-171
20. Cummings S.R., Bates D., and Black D.M. Clinical use of bone densitometry. JAMA 288 (2002) 1889-1897
21. Wilkins C.H., and Birge S.J. Prevention of osteoporotic fractures in the elderly. Am J Med 118 (2005) 1190-1195
22. Optimal calcium intake. NIH Consensus Statement. June 6-8 1994;12(4):1-31.
23. LeBoff M.S., Kohlmeier L., Hurwitz S., Franklin J., Wright J., and Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 281 (1999) 1505-1511
24. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 62 (2005) 265-281
25. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 291 (2004) 1999-2006
26. Avenell A., Gillespie W.J., Gillespie L.D., and O'Connell D.L. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 3 (2005) CD000227
27. Kantor S.M., Ossa K.S., Hoshaw-Woodard S.L., and Lemeshow S. Height loss and osteoporosis of the hip. J Clin Densitom 7 (2004) 65-70
28. Green A.D., Colon-Emeric C.S., Bastian L., Drake M.T., and Lyles K.W. Does this woman have osteoporosis?. JAMA 292 (2004) 2890-2900
29. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353 (2005) 595-603
30. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., and Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 16 (2005) 713-716
31. Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., Delmas P., et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 20 (2005) 1185-1194
32. Siris E.S., Chen Y.T., Abbott T.A., Barrett-Connor E., Miller P.D., Wehren L.E., et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164 (2004) 1108-1112
33. US Preventive Services Task Force. Clinical guidelines: screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 137 (2002) 526-528
34. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
35. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis. 2001 edition, with selected updates for 2003. Endocr Pract 9 (2003) 544-564
36. Lewiecki E.M., Richmond B., and Miller P.D. Uses and misuses of quantitative ultrasonography in managing osteoporosis. Cleve Clin J Med 73 (2006) 742-746
37. Genant H.K., and Jiang Y. Advanced imaging assessment of bone quality. Ann N Y Acad Sci 1068 (2006) 410-428
38. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?. Bone 41 (2007) 308-317
39. Small Jr. W., and Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research?. JAMA 294 (2005) 2635-2637
40. Greep N.C., Giuliano A.E., Hansen N.M., Taketani T., Wang H.J., and Singer F.R. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 114 (2003) 653-659
41. Pfeilschifter J., and Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18 (2000) 1570-1593
42. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
43. Lin N.U., and Winer E.P. Advances in endocrine therapy for postmenopausal women. J Clin Oncol 26 (2008) 798-805
44. Van Pottelbergh I., Goemaere S., and Kaufman J.M. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88 (2003) 3075-3081
45. Smith M.R. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 12 (2006) 6315s-6319s
46. Qaseem A., Snow V., Shekelle P., Hopkins Jr. R., Forciea M.A., and Owens D.K. Clinical Efficacy Assessment Subcommittee American College of Physicians. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148 (2008) 680-684
47. Canalis E., and Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86 (2001) 5681-5685
48. American College of Rheumatology Ad Hoc Committee on Glucocorticoid Induced Osteoporosis. Recommendations for the prevention and treatment of glucocoriticoid induced osteoporosis. Arthritis Rheum 44 (2001) 1496-1503
49. Heffernan M.P., Saag K.G., Robinson J.K., and Callen J.P. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA 295 (2006) 1300-1303
50. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 (2008) 420-432
51. Holmberg L., and Anderson H. HABITS Steering and Data Monitoring Committees. HABITS (Hormonal Replacement Therapy After Breast Cancer-Is It Safe?), a randomised comparison: trial stopped. Lancet 363 (2004) 453-455
52. O'Regan R.M., Gajdos C., Dardes R.C., De Los Reyes A., Park W., Rademaker A.W., et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94 (2002) 274-283
53. Van Poznak C., and Sauter N.P. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 104 (2005) 443-456
54. Diamond T.H., Higano C.S., Smith M.R., Guise T.A., and Singer F.R. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100 (2004) 892-899
55. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 (2007) 1033-1046
56. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
57. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
58. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
59. Coleman R.E., Banks L.M., Girgis S.I., Kilburn L.S., Vrdoljak E., Fox J., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
60. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
61. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
62. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
63. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
64. Ellis G., Bone H.G., Chlebowski R., Paul D., Spadafora S., Smith J., et al. A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for non metastatic breast cancer [abstract]. Breast Cancer Res Treat 106 (2007) 47
65. Lester J., Dodwell D., Purohit O.P., Gutcher S.A., Ellis S.P., Thorpe R., et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study [abstract]. J Clin Oncol 26 (2008) 554
66. Greenspan S.L., Brufsky A., Lembersky B.C., Bhattacharya R., Vujevich K.T., Perera S., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26 (2008) 2644-2652
67. Van Poznak C., Hannon R.A., Clack G., Campone M., Mackey J.R., Apffelstaedt J., et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis [abstract 502]. Breast Cancer Res Treat 106 (2007) S37
68. Brufsky A., Harker W.G., Beck J.T., Carroll R., Tan-Chiu E., Seidler C., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
69. Greenspan S.L., Nelson J.B., Trump D.L., and Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146 (2007) 416-424
70. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
71. Diamond T.H., Winters J., Smith A., De Souza P., Kersley J.H., Lynch W.J., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 (2001) 1444-1450
72. Smith M.R., Fallon M.A., Lee H., and Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 3841-3846
73. Taxel P., Dowsett R., Albertsen P., Fall P., Biskup B., and Raisz L.G. Risedronate prevents early bone loss and increased turnover in men receiving LHRH-agonist therapy for prostate cancer. J Bone Miner Res Suppl 1 (2006) SU062
74. Smith M.R., Malkowicz S.B., Chu F., Forrest J., Price D., Sieber P., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179 (2008) 152-155
75. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012